Aclaris Therapeutics announced leadership changes and that it is undertaking a strategic review of its business. Aclaris and Douglas Manion, M.D. have mutually agreed that Dr. Manion will step down as Aclaris’ CEO and President and member of the Board of Directors, effective immediately. In connection with his departure, the Board has appointed Dr. Neal Walker, Aclaris’ Chairman of the Board of Directors, as Interim CEO Dr. Walker is a co-founder of Aclaris, has served as a member of the Board of Directors since its inception, and previously served as Aclaris’ CEO until 2022.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ACRS:
- Aclaris Therapeutics downgraded to Neutral from Buy at BTIG
- Aclaris downgraded to Hold at Jefferies after ATI-1777 data reported
- Aclaris Therapeutics downgraded to Hold from Buy at Jefferies
- Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
- Aclaris announces Phase 2b study of ATI-1777 met primary efficacy endpoint
